Compare prices and buy Pancragen from 2 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic tetrapeptide (Lys-Glu-Asp-Trp-NH2 / KEDW-NH2, a C-terminal amide) in the Khavinson short-peptide family, associated with pancreatic tissue. Reported in Russian preclinical studies to modulate pancreatic-islet function and glucose homeostasis. Part of the Cytogen class of ultra-short peptide bioregulators. It has no FDA approval.
For research purposes only. Not medical advice.
Pancragen is a synthetic tetrapeptide from Vladimir Khavinson's short-peptide program, catalogued with the rest of the family in Longevity and Bioregulators. The group's 2022 review in the International Journal of Molecular Sciences lists it as KEDW-NH2, Lys-Glu-Asp-Trp with a C-terminal amide, and labels it a regulator of pancreatic functions, citing the group's 2020 review of peptide-driven cell differentiation.
The amide is part of the identity. The developers' US patent, US 7,491,703, granted in 2009, names the compound lysyl-glutamyl-aspartyl-tryptophan amide and gives the formula C26H37N7O8 and a molecular weight of 575.62. PubChem's record for that structure has the same formula but carries no trade name or CAS number. The free acid, Lys-Glu-Asp-Trp without the amide, is a separate PubChem compound with the formula C26H36N6O9.
Pancragen shares its first three residues with Testagen and with Livagen, which the same 2022 table lists as KEDA and labels a hepatoprotector. The fourth residue, and Pancragen's amide, set them apart.
Each study below lists Khavinson among its authors, and all of them are preclinical.
The developers propose that the peptide acts on gene expression by binding DNA. Their 2021 review in Molecules summarizes a 2015 paper in which spectroscopy and molecular modeling placed its binding at the DNA sequence ACCT, which the authors report in promoter regions of genes for pancreatic cell function, and in which it raised expression of nine such genes, among them PDX1 and NGN3 (Khavinson, American Journal of Biomedical Sciences, 2015). An earlier modeling study by the group had named GGCAG as the putative binding site (Tarnovskaya, Bulletin of Experimental Biology and Medicine, 2014).
PeptideScouter found two reports describing patients, and Khavinson is named on both.
PeptideScouter found no US regulatory record for Pancragen. As of October 21, 2026, it appears in none of these:
It marks a C-terminal amide. Pancragen's developers list it as KEDW-NH2, the tetrapeptide Lys-Glu-Asp-Trp with the carboxyl group at its tryptophan end replaced by an amide. Their 2009 US patent gives the amide the formula C26H37N7O8 and a molecular weight of 575.62. The same four residues without the amide form a different compound, the free acid, with the formula C26H36N6O9.
PeptideScouter found two reports, both co-authored by Vladimir Khavinson, its developer. A 2009 US patent naming him as an inventor describes a hospital study of 36 patients with type 1 or type 2 diabetes, split at random into two groups, in which the daily insulin dose fell after a 10-day course in 8 of 16 insulin-treated patients given the peptide and in none of 16 controls given saline. A 2011 study at the Institute of Gerontology in Kyiv, which examined 33 older patients with type 2 diabetes, reports lower fasting glucose, insulin and insulin resistance with the peptide, but its abstract does not say how many patients received it or how they were assigned. ClinicalTrials.gov lists no study under its name or its sequence as of October 2026.
PeptideScouter found no US regulatory record for it. As of October 21, 2026, Pancragen does not appear in Drugs@FDA, in either table of FDA's Category 2 list of bulk drug substances raising significant safety risks, in FDA's lists of substances nominated for compounding under Sections 503A and 503B, or in the records of FDA's Pharmacy Compounding Advisory Committee meetings of October and December 2024 and July 2026. FDA's substance registry has no record of it, ClinicalTrials.gov lists no study of it and no FDA warning letter names it.
All three come from Vladimir Khavinson's short-peptide program and share their first three residues, Lys-Glu-Asp. The developers' 2022 review table lists Pancragen as KEDW-NH2, Livagen as KEDA and Testagen as KEDG, so each has a different fourth residue, and only Pancragen carries a C-terminal amide. The same table assigns them to different tissues, Pancragen as a regulator of pancreatic functions, Livagen as a hepatoprotector and Testagen as a regulator of the male reproductive system. They are separate compounds with different formulas.
Pancragen is sold by 2 research peptide vendors indexed on PeptideScouter, with 2 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 2 indexed research peptide vendors currently have Pancragen in stock. Stock state is refreshed daily from each vendor's catalog.
Swiss Chems currently lists Pancragen at $3.00/mg, the lowest listed price across 2 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.70/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 2 vendors listing Pancragen publish a PeptideScouter code, worth 10% off. Applied, the lowest effective price falls from $3.00/mg listed to $2.70/mg at Swiss Chems. Each vendor's code is shown beside its price in the table above.
Pancragen ranges from $3.00/mg to $3.25/mg across 2 listings from 2 research peptide vendors, normalized to USD per milligram and refreshed daily.
2 research peptide vendors currently list Pancragen on PeptideScouter. We track 2 listings across size and kit variants.
